Groundbreaking treatments for Alzheimer’s disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer’s experts told Reuters. Crystal Glover, a social psychologist and expert in equity in aging research who leads clinical trial recruitment of the Rush Alzheimer’s Disease Research Center in Chicago, asked: “Is this even applicable to the groups that are most at risk?”About 20% of older Black people are estimated to have Alzheimer’s or another dementia, twice the rate of white people and above the 14% of Hispanics. Reisa Sperling of Brigham and Women’s Hospital, who is leading the trial of Leqembi to prevent Alzheimer’s dementia